Empagliflozin as monotherapy or add-on therapy in South Asian patients with Type 2 diabetes: post hoc analysis of pooled data from four phase III trials

被引：0
|
作者：
Khunti, K. [1 ]
Asaro-Harris, A. [2 ]
Spencer, W. [3 ]
Pfarr, E. [4 ]
Naderali, E. [2 ]
Salsali, A. [5 ]
Hach, T. [4 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Eli Lilly & Co, Basingstoke, Hants, England
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
来源：
DIABETIC MEDICINE | 2015年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P217
引用
收藏
页码：96 / 97
页数：2
相关论文
共 50 条
  • [1] EFFICACY AND SAFETY OF EMPAGLIFLOZIN IN ASIAN PATIENTS WITH TYPE 2 DIABETES: POOLED DATA FROM FOUR PHASE III TRIALS
    Yoon, K. -H.
    Nishimura, R.
    Weng, J. P.
    Lee, J. S.
    Crowe, S.
    Salsali, A.
    Hach, T.
    Woerle, H. J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S20 - S21
  • [2] Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials
    Yoon, Kun-Ho
    Nishimura, Rimei
    Lee, Jisoo
    Crowe, Susanne
    Salsali, Afshin
    Hach, Thomas
    Woerle, Hans J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (10): : 1045 - 1049
  • [3] Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials
    Lund, Soren S.
    Sattar, Naveed
    Salsali, Afshin
    Neubacher, Dietmar
    Ginsberg, Henry N.
    DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2763 - 2774
  • [4] Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of phase I-III clinical trials
    Yabe, D.
    Yasui, A.
    Ji, L.
    Lee, M. -K.
    Ma, R.
    Chang, T. -J.
    Okamura, T.
    Zeller, C.
    Kaspers, S.
    Lee, J.
    Kohler, S.
    Seino, Y.
    DIABETOLOGIA, 2018, 61 : S307 - S307
  • [5] Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I-III clinical trials
    Yabe, Daisuke
    Yasui, Atsutaka
    Ji, Linong
    Lee, Moon-Kyu
    Ma, Ronald Ching Wan
    Chang, Tien-Jyun
    Okamura, Tomoo
    Zeller, Cordula
    Kaspers, Stefan
    Lee, Jisoo
    Kohler, Sven
    Seino, Yutaka
    JOURNAL OF DIABETES INVESTIGATION, 2019, 10 (02) : 418 - 428
  • [6] Empagliflozin improves glycaemic parameters and cardiovascular risk factors in patients with type 2 diabetes: pooled data from four pivotal phase III trials
    Hach, T.
    Gerich, J.
    Salsali, A.
    Kim, G.
    Hantel, S.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2013, 56 : S377 - S378
  • [7] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
    Sven Kohler
    Cordula Zeller
    Hristo Iliev
    Stefan Kaspers
    Advances in Therapy, 2017, 34 : 1707 - 1726
  • [8] Analysis of empagliflozin vs placebo by Quality and Outcomes Framework targets: post hoc analysis of pooled data from phase III trials
    Brice, R.
    Hassan, S. W.
    Bingham-Gardiner, P.
    Crowe, S.
    Hach, T.
    Salsali, A.
    Naderali, E.
    DIABETIC MEDICINE, 2015, 32 : 96 - 96
  • [9] Safety and Tolerability of Empagliflozin in East Asian Patients with Type 2 Diabetes-Pooled Analysis of Phase I-III Clinical Trials
    Yasui, Atsutaka
    Yabe, Daisuke
    Ji, Linong
    Lee, Moon-Kyu
    Ma, Ronald C.
    Chang, Tien-Jyun
    Okamura, Tomoo
    Zeller, Cordula
    Kaspers, Stefan
    Lee, Jisoo
    Kohler, Sven
    Seino, Yutaka
    DIABETES, 2018, 67
  • [10] Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
    Zinman, Bernard
    Ahren, Bo
    Neubacher, Dietmar
    Patel, Sanjay
    Woerle, Hans-Juergen
    Johansen, Odd Erik
    CANADIAN JOURNAL OF DIABETES, 2016, 40 (01) : 50 - 57
12345